What type of study is this?

This is a Literature Review study.

August 25, 2025

Ob‐gyns respond to recent FDA discussion on SSRIs in pregnancy

Puntos clave

SSRIs pose minor risks to the fetus and newborn, and their benefits for maternal health are significant.
Research indicates that maternal depression can negatively impact child development, supporting SSRI use.
The FDA's recent discussion has caused confusion among healthcare providers about SSRIs in pregnancy.
Maternal mental health is crucial for the well-being of both mother and child, highlighting the need for careful consideration.

Resumen

When the federal Food and Drug Administration (FDA) recently discussed the use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy, the result was confusion among many. For years, research has shown that risks to the fetus and newborn — and developing child — are minor, and that these risks are outweighed by benefits to the mother. The benefits are to the child as well, because of the risks of maternal depression on children. But the FDA panel specifically discussed the risks of SSRIs in pregnancy.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Alison Knopf (Mon,) studied this question.

synapsesocial.com/papers/68af5d6fad7bf08b1eae1129 https://doi.org/https://doi.org/10.1002/cpu.30999

Preguntar a la IA

Me gusta

Guardar